Overcoming resistance: targeted nanomedicine solutions for cancer therapy
Source abstract
Abstract
Multidrug resistance (MDR), or tumor drug resistance, is still one of the most serious issues in the treatment of cancer, which directly affects the efficacy of cancer therapies and the survival of patients. This review focuses on describing how nanotechnology in medicine may help to address MDR and presents novel approaches that may revolutionize targeted cancer treatment. In this review, we discuss the potential of different types of nanoparticles, such as liposomes, polymeric nanoparticles and metallic nanoparticles for targeted delivery, and the use of these nanoparticles to kill tumor cells without damaging the normal cells. Further, we discuss emerging approaches, including RNA interference, CRISPR-Cas9 gene editing, and stimuli-responsive nanoparticles, all of which indicate future directions for MDR combat. Based on such developments, nanomedicine turns out to be a crucial handle in oncology, end-user for superior and refine style of managing cancer. This review establishes the imperative practicing of transdisciplinary integration in order to attain the optimum advancement of nanomedicine in combating MDR and enhancing the survival prognosis of different forms of cancer in patients all over the world.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Product Development, Frontage Laboratories Inc
Flamma USA Group, Flamma USA
Department of Pharmacy, Bhagwant University
R&D and Alliance Management, Slayback Pharma LLC
American Regent
References (100+)
Show source-provided references
1. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Cancer J. 2014;20(1):48–52.
2. Lage H. Overview of mechanisms contributing to multidrug resistance in cancer. Biochem Pharmacol. 2008;76(6):718–726.
3. 10.1172/JCI908310.1172/JCI9083 ↗
4. 10.1038/nrc265610.1038/nrc2656 ↗
5. Maeda H, Khatami M. The EPR effect and beyond: strategies to improve tumor targeting and delivery of nanomedicines. Adv Drug Delivery Rev. 2018;141:3–31.
6. 10.1016/j.jconrel.2012.03.02010.1016/j.jconrel.2012.03.020 ↗
7. Yin PT, Shah S, Pasquale NJ, et al. Stem cell-based gene therapy activated using magnetic nanoparticles to treat multidrug-resistant cancer. Biomaterials. 2014;35(24):6538–6547.
8. 10.1016/j.nantod.2013.04.00710.1016/j.nantod.2013.04.007 ↗
9. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Cancer Journal. 2014;20(1):48–52.
10. 10.3390/biomedicines910135310.3390/biomedicines9101353 ↗
11. 10.3390/molecules2716525210.3390/molecules27165252 ↗
12. 10.1155/2020/302838710.1155/2020/3028387 ↗
13. 10.20517/cdr.2019.1010.20517/cdr.2019.10 ↗
14. PeaceHealth M, a Bill P. Breast Cancer Treatment (PDQ®). Treatment-health professional information [NCI]. Early Pregnancy. 2024;38(39):40.
15. 10.7759/cureus.2849610.7759/cureus.28496 ↗
16. 10.1038/s12276-022-00863-410.1038/s12276-022-00863-4 ↗
17. 10.1016/j.tranon.2024.10190110.1016/j.tranon.2024.101901 ↗
18. 10.1038/s41392-023-01341-710.1038/s41392-023-01341-7 ↗
19. 10.1002/cam4.569810.1002/cam4.5698 ↗
20. 10.1038/s41392-021-00658-510.1038/s41392-021-00658-5 ↗
21. 10.3390/cancers1404097610.3390/cancers14040976 ↗
22. 10.1186/s12967-023-04575-910.1186/s12967-023-04575-9 ↗
23. 10.1016/j.jconrel.2023.07.03910.1016/j.jconrel.2023.07.039 ↗
24. 10.1080/10717544.2022.211099810.1080/10717544.2022.2110998 ↗
25. 10.1002/wcms.150410.1002/wcms.1504 ↗
26. 10.3390/jpm1108077110.3390/jpm11080771 ↗
27. 10.3390/nano1303057410.3390/nano13030574 ↗
28. 10.1177/1533033823115208310.1177/15330338231152083 ↗
29. 10.3390/ph1603045410.3390/ph16030454 ↗
30. 10.3390/polym1522436910.3390/polym15224369 ↗
31. 10.1002/smtd.20230111210.1002/smtd.202301112 ↗
32. 10.1007/s10895-023-03472-010.1007/s10895-023-03472-0 ↗
33. 10.1016/j.apsb.2022.02.02510.1016/j.apsb.2022.02.025 ↗
34. 10.1016/j.bmt.2023.09.00110.1016/j.bmt.2023.09.001 ↗
35. 10.2147/IJN.S23147910.2147/IJN.S231479 ↗
36. 10.1016/j.lfs.2024.12289910.1016/j.lfs.2024.122899 ↗
37. 10.3390/nano1203039910.3390/nano12030399 ↗
38. 10.3390/molecules2818662410.3390/molecules28186624 ↗
39. 10.3390/ijms2201038510.3390/ijms22010385 ↗
40. 10.1016/j.cbi.2018.07.01510.1016/j.cbi.2018.07.015 ↗
41. 10.3390/ijms2407661510.3390/ijms24076615 ↗
42. 10.1111/cas.1537710.1111/cas.15377 ↗
43. 10.1021/acs.molpharmaceut.9b0122110.1021/acs.molpharmaceut.9b01221 ↗
44. 10.1016/j.biomaterials.2016.06.00210.1016/j.biomaterials.2016.06.002 ↗
45. 10.1166/jbn.2022.326610.1166/jbn.2022.3266 ↗
46. 10.3390/pharmaceutics1003016210.3390/pharmaceutics10030162 ↗
47. 10.3390/pharmaceutics1505140610.3390/pharmaceutics15051406 ↗
48. 10.1016/j.biomaterials.2012.03.01810.1016/j.biomaterials.2012.03.018 ↗
49. 10.3389/fonc.2022.85501910.3389/fonc.2022.855019 ↗
50. 10.3390/biom1506086010.3390/biom15060860 ↗
51. 10.1016/j.drudis.2021.11.01110.1016/j.drudis.2021.11.011 ↗
52. 10.1016/j.nxmate.2024.10012810.1016/j.nxmate.2024.100128 ↗
53. 10.1001/jamaoncol.2018.216810.1001/jamaoncol.2018.2168 ↗
54. 10.3390/molecules2601010010.3390/molecules26010100 ↗
55. 10.3390/pharmaceutics1501023610.3390/pharmaceutics15010236 ↗
56. 10.4172/2157-7439.100016410.4172/2157-7439.1000164 ↗
57. 10.1016/j.carbpol.2019.11574510.1016/j.carbpol.2019.115745 ↗
58. 10.1016/j.addr.2020.07.02210.1016/j.addr.2020.07.022 ↗
59. 10.15252/emmm.20150600610.15252/emmm.201506006 ↗
60. 10.3389/fphar.2022.101594010.3389/fphar.2022.1015940 ↗
61. 10.3390/polym1405093610.3390/polym14050936 ↗
62. 10.3389/fbioe.2023.119740410.3389/fbioe.2023.1197404 ↗
63. 10.7150/ntno.9263910.7150/ntno.92639 ↗
64. 10.22270/jddt.v10i3.397910.22270/jddt.v10i3.3979 ↗
65. 10.4143/crt.2016.28910.4143/crt.2016.289 ↗
66. 10.1158/0008-5472.CAN-15-295110.1158/0008-5472.CAN-15-2951 ↗
67. 10.1002/mabi.20230010210.1002/mabi.202300102 ↗
68. 10.1016/j.nano.2019.02.02110.1016/j.nano.2019.02.021 ↗
69. 10.1200/jco.2016.34.2_suppl.23310.1200/jco.2016.34.2_suppl.233 ↗
70. 10.1158/1538-7445.AM2016-391210.1158/1538-7445.AM2016-3912 ↗
71. 10.3390/pharmaceutics1307100910.3390/pharmaceutics13071009 ↗
72. 10.3390/cells1121343410.3390/cells11213434 ↗
73. 10.2147/IJN.S3835410.2147/IJN.S38354 ↗
74. 10.1016/j.euros.2022.04.01510.1016/j.euros.2022.04.015 ↗
75. Wang L, Ma J, Zhang L, et al. Bispecific antibody nanoparticles for enhanced immune response in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2020;135(5):367–375.
76. 10.3390/ijms24161282710.3390/ijms241612827 ↗
77. 10.1039/d3nh00198a10.1039/d3nh00198a ↗
78. 10.5772/intechopen.10312510.5772/intechopen.103125 ↗
79. 10.1186/s43094-020-00035-z10.1186/s43094-020-00035-z ↗
80. 10.3390/jnt403001610.3390/jnt4030016 ↗
81. 10.1007/978-981-19-9786-0_1310.1007/978-981-19-9786-0_13 ↗
82. 10.1201/9781003438953-110.1201/9781003438953-1 ↗
83. 10.1007/978-981-99-6698-1_910.1007/978-981-99-6698-1_9 ↗
84. Pankaj S, Mukul T. PH dependent release potential of natural polymers in sustained release of ornidazole from colon targeted delivery system. Magnesium. 2019;10(10):10.
85. 10.1007/978-981-99-1949-9_710.1007/978-981-99-1949-9_7 ↗
86. 10.1201/9781003230236-610.1201/9781003230236-6 ↗
87. 10.1201/9781003240037-310.1201/9781003240037-3 ↗
88. 10.37349/emed.2023.0016110.37349/emed.2023.00161 ↗
89. 10.1021/acsomega.4c0605110.1021/acsomega.4c06051 ↗
90. 10.1016/j.ccr.2024.21575410.1016/j.ccr.2024.215754 ↗
91. 10.1093/rb/rbaf03810.1093/rb/rbaf038 ↗
92. 10.1007/s10517-023-05740-210.1007/s10517-023-05740-2 ↗
93. 10.1016/j.ntm.2024.10004010.1016/j.ntm.2024.100040 ↗
94. 10.3390/nano1109245410.3390/nano11092454 ↗
95. 10.3389/fcell.2020.0012610.3389/fcell.2020.00126 ↗
96. 10.3390/ijms2507405710.3390/ijms25074057 ↗
97. 10.1002/btm2.1060010.1002/btm2.10600 ↗
98. 10.1016/j.heliyon.2023.e1382310.1016/j.heliyon.2023.e13823 ↗
99. 10.3390/pharmaceutics1412270310.3390/pharmaceutics14122703 ↗
100. 10.3390/pharmaceutics1506177210.3390/pharmaceutics15061772 ↗